Detection of minimal malignant cell infiltration in the bone marrow of patients with solid tumours, non-Hodgkin lymphomas and leukaemias.
Detection of a minimal malignant cell infiltration is becoming essential in oncohaematology, either as a prognostic factor in solid tumours or as a criterion of response to therapy in both haematological and non-haematological malignant proliferations. Evaluation of the efficiency of new therapeutic protocols, especially those involving high-dose chemotherapy and allogeneic or autologous bone marrow transplantation, requires agreement between the different investigators on the definition of minimal residual disease in the bone marrow, on the limits of detection of the various available methods and on the types of investigations required in each clinical situation. This report summarizes the conclusions reached at the First France-Autogreffe Meeting on Minimal Residual Disease in the Bone Marrow.